0001367644-23-000124.txt : 20230613 0001367644-23-000124.hdr.sgml : 20230613 20230613212242 ACCESSION NUMBER: 0001367644-23-000124 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230609 FILED AS OF DATE: 20230613 DATE AS OF CHANGE: 20230613 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Glessner Coleen CENTRAL INDEX KEY: 0001919170 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 231012825 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DRIVE STREET 2: SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: 240-631-3200 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 4 1 wk-form4_1686705752.xml FORM 4 X0407 4 2023-06-09 0 0001367644 Emergent BioSolutions Inc. EBS 0001919170 Glessner Coleen 400 PROFESSIONAL DRIVE SUITE 400 GAITHERSBURG MD 20879 0 1 0 0 EVP, Quality & Ethics, and CPL 0 Common Stock 2023-06-09 4 A 0 15385 0 A 134579 D Common Stock 2023-06-09 4 A 0 30770 0 A 165349 D Employee Stock Option (Right to buy) 8.39 2023-06-09 4 A 0 30770 0 A 2030-06-08 Common Stock 30770 62113 D Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Represents the corrected number of securities owned due to a computational error in prior Form-4s Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Vests in three equal installments beginning on the day prior to the anniversary date of the grant. /s/ Jennifer Lynne Fox, Attorney-in-fact 2023-06-13